Dovitinib in Neuroendocrine Tumors
This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.
Advanced Metastatic Paraganglioma|Advanced Metastatic Pheochromocytoma|Recurrent Paraganglioma|Recurrent Pheochromocytoma|Unresectable Paraganglioma|Unresectable Pheochromocytoma
DRUG: Dovitinib
to determine the objective response rate of dovitinib in subjects with advanced malignant pheochromocytoma or paraganglioma, using RECIST criteria, 2 years
This investigator-initiated study is being conducted to evaluate whether the investigational drug, Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors (advanced malignant pheochromocytoma or paraganglioma). The primary endpoint will be response rate (Complete + Partial Response) determined by RECIST v 1.1. 25 subjects will be enrolled on this study at the University of Pennsylvania.